Kevin Astle, Pharm.D., discussed on-demand HIV preexposure prophylaxis (PrEP), the advent of long-term injectables, and updated CDC guidelines at the AMCP Nexus 2022 meeting in National Harbor, Maryland.
This interview was recorded prior to the meeting.
When the Centers for Disease Control and Prevention (CDC) updated its guidelines for HIV preexposure prophylaxis (PrEP) late last year, it greatly expanded the number of people eligible for the strategy of taking HIV antiviral therapy to prevent infection, explains Kevin Astle, Pharm.D., an assistant professor at the University of South Florida Health Taneja College of Pharmacy in Tampa, Florida.
In an interview with Managed Healthcare Executive® recorded before his talk at at the AMCP Nexus 2022 meeting in National Harbor, Maryland, Astle noted that previous guidelines focused on men who have sex with men and IV drug users. The newer guidelines expand the PrEP-eligible population to include anyone who has multiple sexual partners in the last six months, he said.
"We're going to see a much larger population of patients eligible for PrEP," said Astle.
Astle also described long-acting injectable HIV PrEP as a "game changer." The FDA approved the Apretude (cabotegravir extended-release injectable suspension) in December 2021.
He also discussed on-demand PrEP, which involves taking two antiviral pills before having sex and then one per pill per day for two days afterward.